Home›Stock Screener›Beta Drugs›Financial Statements

Beta Drugs Financial Statements

9 Years of Data
2026 - 2018

Beta Drugs financial statements. In FY2026, Beta Drugs (BETA) reported revenue ₹139 Cr, net profit ₹19 Cr and EPS ₹16.59, with a net profit margin of 13.7% and ROE of 7.8%. Full financial statements from FY2018 to FY2026 (9 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore BETA fundamental worth to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 13.67% 2026 data
EBITDA Margin 23.02% 2026 data
Operating Margin 22.00% 2026 data
Return on Assets 3.83% 2026 data
Return on Equity 7.76% 2026 data

Balance Sheet Ratios

Equity Ratio 49.40% 2026 data
Asset Turnover 0.28 2026 data

BETA Revenue, Net Profit & EBITDA — Year-on-Year Growth

BETA YoY (Sept 2025 vs Sept 2026) — revenue +31.1%, net profit +58.3%, EBITDA +33.3%, expenses +30.5%. See BETA price book multiple to compare market price against book value per share.

Revenue Growth
+31.1%
Year-over-Year
Net Profit Growth
+58.3%
Year-over-Year
EBITDA Growth
+33.3%
Year-over-Year
Expense Growth
+30.5%
Year-over-Year
Assets Growth
+13.8%
Year-over-Year
Equity Growth
+24.4%
Year-over-Year
Operating Cash Flow Growth
+16.1%
Year-over-Year
Investing Cash Flow Growth
-157.1%
Year-over-Year
Financing Cash Flow Growth
+1575.0%
Year-over-Year

BETA Income Statement — Revenue, EBITDA & Net Profit

Beta Drugs revenue ₹139 Cr, EBITDA ₹32 Cr, net profit ₹19 Cr, EPS ₹16.59 (2026) — net profit margin 13.7%. For live price, earnings ratios and company overview, see BETA share price screener.

Periods ₹ Crores
Particulars Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Dec 2024
Revenue 139 97 127 106 98 103 90 89
Expenses 107 76 98 82 79 81 70 72
EBITDA 32 21 29 24 19 23 19 17
Operating Profit Margin % 22.00% 19.00% 22.00% 21.00% 16.00% 20.00% 19.00% 18.00%
Depreciation 5 5 4 4 4 4 4 3
Interest 2 4 3 4 3 3 4 2
Profit Before Tax 26 12 22 16 12 16 11 12
Tax 7 3 6 4 3 4 2 3
Net Profit 19 9 17 12 9 12 9 9
Earnings Per Share (₹) 16.59 8.93 14.78 12.10 9.40 11.59 8.40 9.31

BETA Balance Sheet — Assets, Liabilities & Shareholders' Equity

BETA total assets ₹496 Cr, total equity ₹245 Cr, total liabilities ₹ Cr (2026) — ROE 7.8%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018
ASSETS
Total Assets 496 436 254 198 158 118 107 83 50
Current Assets
Fixed Assets 125 89 65 63 55 40 44 18 13
Capital Work in Progress 0 0 0 0 0 3 0 15 1
Investments 75 0 0 0 0 0 0 0 0
Other Assets 0 347 190 136 103 75 63 50 35
LIABILITIES
Total Liabilities
Current Liabilities 143 136 12 13 17 16 13 9 3
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 245 197 157 123 92 69 57 41 33
Share Capital 10 10 10 10 10 10 10 9 9
Reserves & Surplus 235 187 148 113 83 59 48 32 24

BETA Cash Flow Statement — Operating, Investing & Financing

Beta Drugs operating cash flow ₹36 Cr, investing ₹-36 Cr, financing ₹118 Cr, net cash flow ₹118 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018
Operating Activities 36 31 23 30 19 8 0 17
Investing Activities -36 -14 -19 -22 -6 -15 -21 -11
Financing Activities 118 -8 -3 -1 -8 9 12 5
Net Cash Flow 118 10 2 7 5 2 -9 12